An experimental medication that was recently shown to slow the progression of the neurodegenerative disease amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, has now demonstrated the potential to also prolong patient survival.Learn More
Sean M. Healey & AMG Center for ALS
News & Events
Recent Media CoverageView All
Following up on earlier findings, a new study led by Sabrina Paganoni, MD, PhD at the Healey Center for ALS shows that treatment AMX0035 may extend life as well as slowing the progression of ALS.
Merit Cudkowicz, MD, MSc, Mass General Chief of Neurology and Director of the Healey Center for ALS, is recognized as one of 10 leaders transforming health care.
Make a Difference for the Healey Center
Join our quest to discover life-saving therapies for individuals who are affected by ALS. The key to our success is our dedication to collaboration. At the Sean M. Healey and AMG Center for ALS at Mass General, we partner with the best clinician-scientists, our patients and friends like you to turn laboratory successes into promising therapies.